R S Kaplan Selected Research

XELOX

1/2009

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R S Kaplan Research Topics

Disease

3	Neoplasms (Cancer) 01/2001 - 02/2000
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Coronary Artery Disease (Coronary Atherosclerosis) 08/2015
1	Nausea 01/2009
1	Colorectal Neoplasms (Colorectal Cancer) 01/2009
1	Vomiting 01/2009
1	Margins of Excision 07/2000

Drug/Important Bio-Agent (IBA)

2	Cytotoxins (Cytolysins)IBA 01/2001 - 02/2000
1	cediranib (AZD2171)IBA 01/2021
1	PlatinumIBA 01/2021
1	Cetuximab (Erbitux)FDA Link 01/2009
1	XELOXIBA 01/2009
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2009
1	Antineoplastic Agents (Antineoplastics)IBA 01/2001
1	Cytostatic AgentsIBA 01/2001
1	Prostate-Specific Antigen (Semenogelase)IBA 07/2000
1	DNA (Deoxyribonucleic Acid)IBA 07/2000

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2021
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 08/2015
1	Therapeutics 01/2009